Sygnature Discovery and RenaSci Establish Strategic Alliance focused on Metabolic and CNS Disorders

15th February 2016 – Nottingham, UK – Sygnature Discovery Limited, a company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, from target validation to development candidate, and RenaSci Limited, a company providing an integrated blend of consultancy and experimental services to the global pharmaceutical industry to help maximise research productivity and […]

Sygnature Discovery delivers over 21K novel compounds to the European Lead Factory, one of the top performing SMEs in the consortium

Nottingham, UK – 3rd February 2016 Sygnature Discovery has announced that is has delivered in excess of 21,000 novel chemical compounds to the Public Compound Collection (PCC) of the European Lead Factory (ELF). The ELF, initiated in 2013, is a €196 million collaborative venture financed by the Innovative Medicines Initiative (IMI) and is aimed at […]

Sygnature Discovery starts 2016 with two key appointments as expansion continues.

Dr Stephen Young has been appointed as Vice-President, Business Development, joining from Chinese CRO start-up, Hitgen where he was VP of Business Development and responsible for establishing several early research collaborations. Prior to working at Hitgen, Stephen has held business development positions at Pharmacia, Novabiochem and Protherics. Stephen is a highly experienced Medicinal Chemist and […]

Sygnature Discovery’s group invests in new start up, Peak Proteins

 Nottingham, UK and Alderley Park, UK – 25th January 2016 – Sygnature Discovery, the UK’s largest independent provider of drug discovery expertise has invested, through it’s parent Sygil Group, in a new start-up company. The investment in Peak Proteins Ltd is part of an ongoing strategy to build and expand the Group’s extensive capabilities. The deal, which […]

Scientific publication confirms the truly unique nature of the public screening collection assembled in the European Lead Factory

A scientific publication released this month in “Drug Discovery Today” details the results of a benchmark study performed on the screening collection being currently designed and synthesised within the European Lead Factory Consortium of which Sygnature Discovery is very proud to be a part.   Dr Simon Hirst, Founder and Chief Executive Officer of Sygnature […]

Page 5 of 10« First...34567...10...Last »
Copyright © 2017 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.